New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!
AVE's Principal Activity is the development, production, sale and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skin care and animal health and nutrition industries.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+433.20%|
|vs ASX 200 (1yr)||+428.06%|
|ASX Rank||1494 of 2,466|
|Sector Rank||129 of 177|
Avecho Biotechnology Limited (AVE , formerly Phosphagenics Limited) develops and commercialises Human and Animal Health products using its proprietary drug delivery system called TPM (Targeted Penetration Matrix).
Incorporated in VIC on 19/06/1992 as Greenchip Development Capital Ltd. Name changed to Vital Capital Limited on 27/04/1999. Name changed to Phosphagenics Limited on 10/2/2004. Changed GICS from 4020 Diversified Financials to 3520 Pharmaceuticals & Biotechnology on 4/3/2005.
See Upcoming Dividends for all ASX companies.
|Dividend yield||0 %|
|Mr Matthew Patrick McNamara||Non-Executive Director||Jan 2020||
Mr Matthew Patrick McNamara
Mrt McNamara has over 30 years' experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd. He has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.
|Dr Gregory (Greg) Collier||Non-Executive Chairman, Non-Executive Director||Apr 2019||
Dr Gregory (Greg) Collier
Non-Executive Chairman, Non-Executive Director
Dr Collier has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto.
|Mr David Segal||Non-Executive Director||May 2016||
Mr David Segal
Mr Segal was the Investor Relations Manager at Phosphagenics from 2011 to 2015. Prior to this he worked for over 30 years in stockbroking, including setting up, raising capital for and running Trent Securities which was absorbed into Shaw Stockbroking in 1992. Mr Segal has been a shareholder of Phosphagenics since 1999.
|Professor Andrew Lancelot Vizard||Non-Executive Chairman, Non-Executive Director||Nov 2015||
Professor Andrew Lancelot Vizard
Non-Executive Chairman, Non-Executive Director
Professor Vizard is a Principal Fellow at the Faculty of Veterinary and Agricultural Sciences, University of Melbourne and previously Associate Professor of Veterinary Epidemiology and Director of The Mackinnon Project. He is an experienced company director and has previously held directorships in Animal Health Australia and Primesafe. In the previous four years, Professor Vizard was a non-executive director of the Ridley Corporation Limited. He is Member of Risk Management Committee.
|Dr Ross Murdoch||Non-Executive Director||Apr 2015||
Dr Ross Murdoch
Dr Murdoch joined Phosphagenics as CEO in January 2015 and was appointed as director in April 2015. He has more than 25 years' experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia.
|Mr Lawrence Gozlan||Non-Executive Director||Aug 2011||
Mr Lawrence Gozlan
Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.
|Mr Donald Ian Clarke||Non-Executive Director, Non-Executive Deputy Chairman||Aug 2009||
Mr Donald Ian Clarke
Non-Executive Director, Non-Executive Deputy Chairman
Mr Clarke is s a lawyer and company director. In addition to being a consultant to the law firm, Minter Ellison (having retired on 30 June 2015 after 27 years as a corporate partner of the firm), Don is a director of the listed companies, Zoono Group Limited and Contango Income Generator Limited, and two other unlisted public companies. He has extensive commercial law and business experience from over 30 years advising ASX listed and private companies.
|Mr Jonathan Lancelot Addison||Non-Executive Director||Apr 2005||
Mr Jonathan Lancelot Addison
Mr Addison has over 34 years of experience in the investment management industry. He is Investment consultant and former CEO of the Meat Industry Employees Superannuation Fund. Previous experience includes Director and Asset consultant with the Corporate Finance Section of Pricewaterhouse Coopers and Manager at Sedgwick Noble Lowndes. He is Chairman of Gardior Pty Ltd, Chairman and Member of Investment, Committee of Centaur Property Funds Management Ltd, Director CHIF Pty Ltd and Director Ballarat Water Pty Ltd.
The current holdings of AVE directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Gregory (Greg) Collier||31/12/2019||N/A||2,000,000||2,250,000||N/A|
Data supplied by Morningstar and accurate on Feb 21, 2020.
It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).
|Mr Mark Gregory Kerr (Lindmark Inv Staff S/F A/C)||93,071,745||5.90%|
|HSBC Custody Nominees (Australia) Limited||86,209,916||5.47%|
|Mr Mark Gregory Kerr & Mrs Linda Marie Kerr (Lindmark Inv Staff S/F A/C)||67,153,797||4.26%|
|BNP Paribas Noms Pty Ltd (DRP)||41,991,591||2.66%|
|Paradyce Pty Ltd (The Paradyce A/C)||38,600,000||2.45%|
|Rosscope Pty Ltd (Ross Copeland Family A/C)||30,558,184||1.94%|
|Mr Ross Copeland & Mrs Gina Copeland||23,018,212||1.46%|
|ACK Pty Ltd (Markoff Super No 2 A/C)||20,494,147||1.30%|
|Kazakco Pty Ltd (Kent Family A/C)||20,000,000||1.27%|
|Citicorp Nominees Pty Limited||19,944,950||1.26%|
|Churchcourt Pty Limited||19,162,500||1.21%|
|Mr Ross Graham Copeland & Mrs Gina Copeland (Publicity Press S/F A/C)||16,868,545||1.07%|
|Mr Brandon Armon Batagol||16,005,597||1.01%|
|Dr Maurice Arthur Trewhella & Mrs Elizabeth Trewhella (Simpetejen Super Fund A/C)||16,000,000||1.01%|
|Servbond Pty Limited (Servbond Pty Ltd S/F A/C)||16,000,000||1.01%|
|Citycastle Pty Ltd||15,600,000||0.99%|
|BHL Pension Pty Ltd (BHL Pension Fund A/C)||15,000,000||0.95%|
|Mr Gary Dean Shaw||15,000,000||0.95%|
|Mrs Susan Margaret Chudleigh & Mr John West Chudleigh||14,000,000||0.89%|
|J P Morgan Nominees Australia Pty Limited||13,166,434||0.83%|
|Holding Size||1 - 1,000||1,001 - 5,000||5,001 - 10,000||10,001 - 100,000||100,001+||Total|
|No. of Shareholders||459||903||671||2,016||1,188||5,237|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Mark Gregory KERR||21/02/2020||199,503,526||12.65|
No buy transactions reported by Substantial Shareholders in the past 12 months.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.